AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the
“
Company”), a regenerative medicine company
leading the development and commercialization of first-in-class
devices and autologous cellular therapies for skin restoration,
today reported financial results for the first quarter March 31,
2023.
Financial Highlights and Recent Updates
- Commercial revenue, which excludes BARDA revenue, of $10.5
million, a 40% increase compared to $7.4 million for the same
period in 2022
- Total revenue, which includes BARDA revenue, of $10.6 million,
a 40% increase compared to $7.5 million for the same period in
2022
- Gross profit margin was 84% compared to 76% in the same period
in 2022
- Expanded field sales organization from 30 to 69, towards our
goal of 70
- Automated disaggregation device, RECELL GO™, maintains the Food
and Drug Administration (FDA) Breakthrough Device designation
- Appointed two independent members to the Board of Directors,
Cary Vance and Robert McNamara
- As of March 31, 2023, $77.6 million in cash, cash equivalents,
and marketable securities, with no debt
“With a solid first quarter, we are on track to deliver a year
of significant growth revenue,” said Jim Corbett, AVITA Medical
Chief Executive Officer. “The onboarding and training of our
expanded U.S. field sales organization is underway, and we believe
we will be fully prepared for the commercial launch of the soft
tissue repair indication following expected FDA approval in June.
Further, we are on track to submit our PMA supplement to the FDA
for RECELL GO by the end of the second quarter. We believe RECELL
GO is a critical component of our platform and has the potential to
significantly accelerate our growth trajectory.”
Future Milestones
- Expect FDA approval for soft tissue repair indication in June
2023 followed by the commercial launch on July 1, 2023
- Anticipate FDA submission of RECELL GO by June 30, 2023
- Expect FDA approval for vitiligo indication in June 2023;
pursuing site of service reimbursement for the use of RECELL in the
physician office setting, which is expected by 2025
Financial Guidance
- Commercial revenue, which excludes BARDA revenue, for the
second quarter 2023 is expected to be in the range of $10.7 to
$11.7 million
- Commercial revenue, which excludes BARDA revenue, for the full
year 2023, remains unchanged, and is expected to be in the range of
$49 to $51 million
Organizational Update
Mr. Terry Bromley has been promoted to Senior Vice President of
Global Sales and Ms. Debbie Garner has been promoted to Senior Vice
President of Global Marketing and Strategy. Mr. Bromley and Ms.
Garner will report directly to Jim Corbett, Chief Executive Officer
of AVITA Medical.
On May 11, 2023, Ms. Erin Liberto resigned from her position as
Chief Commercial Officer to accept a role with a privately held,
non-competing business.
First Quarter 2023 Financial Results
Our commercial revenue, which excludes BARDA revenue, increased
by 40% to $10.5 million in the three-months ended March 31, 2023,
compared to $7.4 million in the same period in 2022. Total revenue,
which includes BARDA revenue, increased by 40% to $10.6 million
compared to $7.5 million in the same period in 2022.
The gross profit margin was increased by 8% to 84% compared to
76% for the first quarter of 2022.
Total operating expenses for the quarter increased by 22% to
$19.4 million, compared to $16.0 million in the same period in
2022, primarily due to increased field expansion and continued
development of the RECELL GO device for the planned submission in
June 2023.
Net loss decreased by 3% to $9.2 million, or $0.37 per share,
compared to a net loss of $9.5 million, or $0.38 per share, in the
same period in 2022.
Adjusted EBITDA* loss remained flat at $6.4 million.
Webcast and Conference Call Information
The Company will host a conference call to
discuss the first quarter financial results and, recent business
highlights on Thursday, May 11, 2023, at 1:30 p.m. Pacific Time
(being Friday, May 12, 2023, at 6:30 a.m. Australian Eastern
Daylight Standard Time). To access the live call via telephone,
please register in advance using the link here. Upon registering,
each participant will receive an email confirmation with dial-in
numbers and a unique personal PIN that can be used to join the
call. A simultaneous webcast of the call will be available via the
Company’s website at https://ir.avitamedical.com.
Authorized for release by the Chief Executive
Officer of AVITA Medical, Inc.
ABOUT AVITA MEDICAL, INC.AVITA Medical® is
a regenerative medicine company leading the development and
commercialization of devices and autologous cellular therapies for
skin restoration. The RECELL® System technology platform, approved
by the FDA for the treatment of acute thermal burns in both adults
and children, harnesses the regenerative properties of a
patient’s own skin to create Spray-On Skin™ cells. Delivered at the
point-of-care, RECELL enables improved clinical outcomes and
validated cost savings. RECELL is the catalyst of a new treatment
paradigm and AVITA Medical is leveraging its proven and
differentiated capabilities to develop first-in-class cellular
therapies for multiple indications, including soft tissue repair
and repigmentation of stable vitiligo lesions.
AVITA Medical’s first U.S. product, the RECELL System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is approved for acute
partial-thickness thermal burn wounds in patients 18 years of age
and older or application in combination with meshed autografting
for acute full-thickness thermal burn wounds in pediatric and adult
patients. In February 2022, the FDA reviewed and approved the PMA
supplement for RECELL Autologous Cell Harvesting Device, an
enhanced RECELL System aimed at providing clinicians a more
efficient user experience and simplified workflow.
The RECELL System is used to prepare Spray-On Skin™ Cells using
a small amount of a patient’s own skin, providing a new way to
treat severe burns, while significantly reducing the amount of
donor skin required. The RECELL System is designed to be used at
the point of care alone or in combination with autografts depending
on the depth of the burn injury. Compelling data from randomized,
controlled clinical trials conducted at major U.S. burn centers and
real-world use in more than 15,000 patients globally, reinforce
that the RECELL System is a significant advancement over the
current standard of care for burn patients and offers benefits in
clinical outcomes and cost savings. Healthcare professionals should
read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting
Device (https://recellsystem.com) for a full description of
indications for use and important safety information including
contraindications, warnings, and precautions.
In international markets, our products are approved under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, soft tissue repair, vitiligo, and
aesthetics. The RECELL System is TGA-registered in Australia,
received CE-mark approval in Europe and has PMDA approval in
Japan.
To learn more, visit www.avitamedical.com.
* Use of non-GAAP Measure
AVITA Medical’s reported earnings are prepared
in accordance with generally accepted accounting principles in the
United States, or GAAP, and represent earnings as reported to the
Securities and Exchange Commission. AVITA Medical has provided in
this release certain financial information that has not been
prepared in accordance with GAAP. AVITA Medical’s management
believes that the non-GAAP adjusted EBITDA described in the
release, which includes adjustments for specific items that are
generally not indicative of our core operations, provides
additional information that is useful to investors in understanding
AVITA Medical’s underlying performance, business and performance
trends, and helps facilitate period-to-period comparisons and
comparisons of its financial measures with other companies in AVITA
Medical’s industry. However, the non-GAAP financial measures that
AVITA Medical uses may differ from measures that other companies
may use. Non-GAAP financial measures are not required to be
uniformly applied, are not audited and should not be considered in
isolation or as substitutes for results prepared in accordance with
GAAP.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTSThis press release includes forward-looking
statements. These forward-looking statements generally can be
identified by the use of words such as “anticipate,” “expect,”
“intend,” “could,” “may,” “will,” “believe,” “estimate,” “look
forward,” “forecast,” “goal,” “target,” “project,” “continue,”
“outlook,” “guidance,” “future,” other words of similar meaning and
the use of future dates. Forward-looking statements in this press
release include, but are not limited to, statements concerning,
among other things, our ongoing clinical trials and product
development activities, regulatory approval of our products, the
potential for future growth in our business, and our ability to
achieve our key strategic, operational, and financial goal.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Each forward-looking
statement contained in this press release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Applicable
risks and uncertainties include, among others, the timing and
realization of regulatory approvals of our products; physician
acceptance, endorsement, and use of our products; failure to
achieve the anticipated benefits from approval of our products; the
effect of regulatory actions; product liability claims; risks
associated with international operations and expansion; and other
business effects, including the effects of industry, economic or
political conditions outside of the company’s control. Investors
should not place considerable reliance on the forward-looking
statements contained in this press release. Investors are
encouraged to read our publicly available filings for a discussion
of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this
release, and we undertake no obligation to update or revise any of
these statements.
FOR FURTHER INFORMATION:
Investors & MediaAVITA Medical,
Inc.Jessica EkebergPhone +1 661 904
9269investor@avitamedical.commedia@avitamedical.com |
|
|
|
AVITA MEDICAL,
INC.Consolidated Balance
Sheets(In thousands, except share and per share
data)(Unaudited)
|
As ofMarch 31, 2023 |
|
As of December 31, 2022 |
ASSETS |
|
|
|
Cash and cash equivalents |
$ |
28,050 |
|
|
$ |
18,164 |
|
Marketable securities |
|
45,401 |
|
|
|
61,178 |
|
Accounts receivable, net |
|
4,502 |
|
|
|
3,515 |
|
BARDA receivables |
|
516 |
|
|
|
898 |
|
Prepaids and other current assets |
|
1,481 |
|
|
|
1,578 |
|
Inventory |
|
2,811 |
|
|
|
2,125 |
|
Total
current assets |
|
82,761 |
|
|
|
87,458 |
|
Marketable securities long-term |
|
4,189 |
|
|
|
6,930 |
|
Plant and equipment, net |
|
1,333 |
|
|
|
1,200 |
|
Operating lease right-of-use assets |
|
1,815 |
|
|
|
851 |
|
Corporate-owned life insurance asset |
|
1,833 |
|
|
|
1,238 |
|
Intangible assets, net |
|
461 |
|
|
|
465 |
|
Other long-term assets |
|
230 |
|
|
|
122 |
|
Total
assets |
$ |
92,622 |
|
|
$ |
98,264 |
|
LIABILITIES, NON-QUALIFIED DEFERRED COMPENSATION PLAN SHARE
AWARDS AND STOCKHOLDERS' EQUITY |
|
|
|
Accounts payable and accrued liabilities |
|
3,752 |
|
|
|
3,002 |
|
Accrued wages and fringe benefits |
|
3,665 |
|
|
|
6,623 |
|
Current non-qualified deferred compensation liability |
|
2,140 |
|
|
|
78 |
|
Other current liabilities |
|
1,929 |
|
|
|
990 |
|
Total
current liabilities |
|
11,486 |
|
|
|
10,693 |
|
Non-qualified deferred compensation liability |
|
1,165 |
|
|
|
1,270 |
|
Contract liabilities |
|
382 |
|
|
|
698 |
|
Operating lease liabilities, long term |
|
1,235 |
|
|
|
306 |
|
Total
liabilities |
|
14,268 |
|
|
|
12,967 |
|
Non-qualified deferred compensation plan share awards |
|
793 |
|
|
|
557 |
|
Contingencies (Note 12) |
|
|
|
Stockholders' equity: |
|
|
|
Common stock, $0.0001 par value per share, 200,000,000 shares
authorized, 25,327,761 and 25,208,436 shares issued and outstanding
at March 31, 2023 and December 31, 2022, respectively |
|
3 |
|
|
|
3 |
|
Preferred stock, $0.0001 par value per share, 10,000,000 shares
authorized, no shares issued or outstanding at March 31, 2023 and
December 31, 2022. |
|
- |
|
|
|
- |
|
Company common stock held by the non-qualified deferred
compensation plan |
|
(892 |
) |
|
|
(127 |
) |
Additional paid-in capital |
|
342,400 |
|
|
|
339,825 |
|
Accumulated other comprehensive income |
|
7,858 |
|
|
|
7,627 |
|
Accumulated deficit |
|
(271,808 |
) |
|
|
(262,588 |
) |
Total
stockholders' equity |
|
77,561 |
|
|
|
84,740 |
|
Total
liabilities, non-qualified deferred compensation plan share awards
and stockholders' equity |
$ |
92,622 |
|
|
$ |
98,264 |
|
|
|
|
|
AVITA MEDICAL,
INC.Consolidated Statements of
Operations(In thousands, except share and per
share data)(Unaudited)
|
Three- Months Ended |
|
March 31, 2023 |
|
March 31, 2022 |
|
|
|
|
Revenues |
$ |
10,550 |
|
|
$ |
7,539 |
|
Cost of
sales |
|
(1,667 |
) |
|
|
(1,778 |
) |
Gross profit |
|
8,883 |
|
|
|
5,761 |
|
BARDA
income |
|
627 |
|
|
|
734 |
|
Operating expenses: |
|
|
|
Sales and marketing expenses |
|
(6,540 |
) |
|
|
(4,828 |
) |
General and administrative expenses |
|
(8,295 |
) |
|
|
(7,534 |
) |
Research and development expenses |
|
(4,586 |
) |
|
|
(3,620 |
) |
Total
operating expenses |
|
(19,421 |
) |
|
|
(15,982 |
) |
Operating loss |
|
(9,911 |
) |
|
|
(9,487 |
) |
Interest
expense |
|
(4 |
) |
|
|
- |
|
Other
income |
|
725 |
|
|
|
28 |
|
Loss
before income taxes |
|
(9,190 |
) |
|
|
(9,459 |
) |
Provision for income tax |
|
(30 |
) |
|
|
(4 |
) |
Net
loss |
$ |
(9,220 |
) |
|
$ |
(9,463 |
) |
|
|
|
|
Net loss
per common share: |
|
|
|
|
|
|
|
Basic |
$ |
(0.37 |
) |
|
$ |
(0.38 |
) |
Diluted |
$ |
(0.37 |
) |
|
$ |
(0.38 |
) |
|
|
|
|
Weighted-average common shares: |
|
|
|
Basic |
|
25,202,088 |
|
|
|
24,937,999 |
|
Diluted |
|
25,202,088 |
|
|
|
24,937,999 |
|
|
|
|
|
* Total operating expenses include impact of share-based
compensation as follows:
|
Three-Months Ended |
(In
thousands) |
March 31, 2023 |
|
March 31, 2022 |
Sales and marketing expenses |
$ |
325 |
|
|
$ |
329 |
|
General and administrative expenses |
|
2,090 |
|
|
|
2,327 |
|
Research and development expenses |
|
225 |
|
|
|
276 |
|
Total |
$ |
2,640 |
|
|
$ |
2,932 |
|
|
|
|
|
|
|
|
|
Reconciliation of reported Net Loss
(GAAP) to Adjusted EBITDA (NON-GAAP) Measure –
Unaudited
|
Three-Months Ended |
(In
thousands) |
March 31, 2023 |
|
March 31, 2022 |
Net Loss |
$ |
(9,220 |
) |
|
$ |
(9,463 |
) |
Depreciation expense |
|
126 |
|
|
|
129 |
|
Patent Amortization |
|
9 |
|
|
|
34 |
|
Share-based expense |
|
2,640 |
|
|
|
2,932 |
|
Interest Expense |
|
4 |
|
|
|
- |
|
Income Tax Expense |
|
30 |
|
|
|
4 |
|
Adjusted EBITDA (Non-GAAP) |
$ |
(6,411 |
) |
|
$ |
(6,364 |
) |
|
|
|
|
|
|
|
|
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2023 to May 2024